Clinical Trials Logo

Carcinoid Tumors clinical trials

View clinical trials related to Carcinoid Tumors.

Filter by:

NCT ID: NCT01373736 Not yet recruiting - Neuroblastoma Clinical Trials

123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors

Start date: n/a
Phase: Phase 3
Study type: Interventional

The study is designed to study the safety and effectiveness of 123I-MIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroendocrine tumors.

NCT ID: NCT01253161 Completed - Clinical trials for Neuroendocrine Tumors

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

Start date: February 1, 2011
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if the study drug, Pasireotide LAR can shrink or slow the growth of Metastatic Neuroendocrine Carcinomas. The safety of this drug will also be studied. The patient's physical state, changes in the size of the tumor, and laboratory findings taken while on-study will help us decide if Pasireotide LAR is safe and effective.

NCT ID: NCT00947167 Terminated - Neuroblastoma Clinical Trials

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Start date: March 2009
Phase: Phase 2
Study type: Interventional

To determine objective response rates (RR) by RECIST guideline version 1.1 for all patients treated with this strategy consisting of initial therapy with pertuzumab as a single agent and then addition of erlotinib for those who have stable disease or progressive disease at three months (Simon design).

NCT ID: NCT00580320 Completed - Melanoma Clinical Trials

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Start date: September 2004
Phase: Phase 1
Study type: Interventional

Bortezomib will enhance the activity of dacarbazine against melanoma and soft tissue sarcoma. Weekly administration of the combination will prove to be feasible and tolerable at an appropriate dose.

NCT ID: NCT00227136 Terminated - Clinical trials for Neuroendocrine Tumors

Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion

Start date: May 2005
Phase: Phase 3
Study type: Interventional

This is a research study looking at the effect of 5-Hydroxy Tryptophan (5-HTP) on urine excretion of 5-Hydroxyindolacetic acid (5-HIAA). 5-HTP is a common over the counter product that is sold in natural food stores and via the Internet. Increased levels of 5-HIAA in the urine can be found in a specific type of cancer, called carcinoid tumor. This study will examine the effect of oral 5-HTP intake on 5-HIAA excretion. Understanding this effect may help to determine which tests should be done in a patient with increased 5-HIAA excretion who's also taking 5-HTP.

NCT ID: NCT00088595 Completed - Carcinoid Tumors Clinical Trials

Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

Start date: January 2004
Phase: Phase 2
Study type: Interventional

Study evaluating SOM230 in patients with metastatic carcinoid tumors